Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication ofimproving lung function and is found in several asthma-related treatments.

Biotechnology

Health Care

Therapeutics

AreteiaTx

AreteiaTx's headquarters in Bernardsville, NJ, United States

Jorge Bartolome

Tom Denwood

Richard Fires, MBA, GPHR

Peter Wijngaard

Mark Kreston

Christopher Courts, CPA

Calman Prussin, M.D.

Description

People (3)

Kevin Wesbecker CPIM, CSCP

Lex Kay

Peter Wijngaard

Jobs